Implicity raises 35 million euros to expand in the United States

Implicity, a French medical technology company, has raised 35 million euros to accelerate its expansion in the United States and develop new predictive algorithms. The funding round was led by the European fund IRIS, with participation from Five Arrows, the alternative investment arm of Rothschild & Co. This new capital brings the total amount raised by the company since its inception to at least 60 million euros. The Paris-based startup was founded in 2016 by cardiologist Arnaud Rosier and engineer David Perlmutter. Its platform aggregates data generated by cardiac devices from various manufacturers, helping medical teams prioritize their alerts. The company is currently deployed in more than 250 centers, serving over 120,000 patients. The new investment is intended to support the company's move from organizing remote monitoring to anticipating clinical risks. FrenchWeb reported the story. The proliferation of connected heart devices, such as pacemakers, defibrillators, and resynchronization devices, has created a complex environment for remote monitoring teams. These teams often face multiple portals, formats, and alert systems from different manufacturers.

Implicity provides a manufacturer-independent software layer that centralizes transmissions and presents them in a common environment. This allows medical teams to manage their patient queue without constantly switching between different systems. The platform also automates less visible tasks, such as identifying patients whose devices are no longer transmitting, documenting interventions, generating reports, and tracking billing elements. The company states that it is used by more than 250 medical centers in France, Germany, and the United States, up from about 100 during its previous funding round in 2022. The number of patients followed has increased from approximately 60,000 to more than 120,000 over the same period. Implicity's artificial intelligence algorithm, IM007, analyzes electrocardiograms transmitted by certain implantable cardiac monitors to detect rhythm anomalies and reduce false positives. The Food and Drug Administration granted the algorithm a 510(k) clearance in 2021. Regulatory documentation specifies that the results are provided to professionals as an aid and cannot be the sole basis for a diagnosis.

The algorithm does not replace the cardiologist but reorganizes the waiting queue, focusing human resources on situations where medical decision-making is necessary. Implicity highlights a national study linking the use of its platform to clinical and health-economic outcomes. Published in the journal Heart Rhythm, the EVIDENCE-RM study is based on data from 69,394 French patients equipped with an implantable defibrillator or a cardiac resynchronization device. The study compares patients followed using Implicity's universal platform with those managed using conventional manufacturer-specific systems. The authors observed a 26 percent lower all-cause mortality in the group using the universal system, along with a decrease in certain hospitalizations, their duration, and hospital expenses. This result provides Implicity with clinical credibility, although the study is retrospective and observational, establishing an association rather than a mechanical causal link.